About
Tempus Oncology is a precision medicine platform built specifically for oncology providers, combining AI-powered analytics with one of the most comprehensive molecular testing portfolios available. The platform supports the entire patient journey—from early-stage hereditary risk assessment using multi-gene panels (CancerNext®, BRCAplus®) to late-stage treatment selection via FDA-approved sequencing panels like xT CDx (648-gene solid tumor panel), RNA sequencing (xR), and liquid biopsy options for MRD monitoring. Every insight generated by Tempus is grounded in real-world evidence, with findings published in over 2,000 peer-reviewed scientific journals including JAMA Network Open, Journal of Clinical Oncology, and Nature Biotechnology. The platform has demonstrated a 29% improvement in identifying actionable fusions through combined DNA + RNA sequencing, and a 28% reduction in false-positive somatic calls via tumor-normal matched analysis. Tempus integrates seamlessly into existing EHR workflows, allowing oncologists to access test results, clinical insights, and AI-driven treatment recommendations directly within their practice management tools. Tempus Hub provides fast test ordering and patient insight access, while Tempus ONE serves as an AI-enabled clinical assistant for real-time decision support. A transparent financial assistance program ensures all U.S. patients, regardless of insurance status, can access high-quality molecular testing.
Key Features
- Comprehensive Genomic Testing Portfolio: Offers a full range of tests including germline hereditary risk panels (CancerNext®, BRCAplus®), somatic tumor sequencing (xT CDx, xT, xR, xF, xE), liquid biopsy MRD assays (xM), and pharmacogenomics (RightMed®).
- AI-Driven Clinical Insights: Integrates molecular and clinical data to surface actionable insights backed by real-world evidence from 2,000+ peer-reviewed publications, helping oncologists translate genomic findings into treatment decisions.
- EHR Workflow Integration: Connects directly with existing electronic health record systems so oncologists can access patient insights, order tests, and act on recommendations without leaving their clinical workflows.
- Tempus ONE AI Clinical Assistant: An AI-enabled assistant that puts patient insights and current treatment options at the clinician's fingertips in real time, supporting faster and more informed decision-making at the point of care.
- Financial Assistance Program: All U.S. patients are eligible to apply for financial assistance regardless of insurance status, removing cost as a barrier to accessing high-quality molecular oncology testing.
Use Cases
- Oncologists ordering comprehensive tumor profiling to identify actionable mutations and guide targeted therapy selection for solid tumor patients.
- Cancer genetics counselors using hereditary risk panels (CancerNext®, BRCAplus®) to assess patient and family risk for inherited cancer syndromes.
- Medical oncologists monitoring minimal residual disease (MRD) and treatment response in cancer patients using liquid biopsy assays.
- Cancer centers integrating Tempus into their EHR to streamline genomic test ordering, results access, and clinical decision support across their oncology practice.
- Research teams leveraging Tempus's real-world molecular and clinical dataset to support translational oncology research and publication.
Pros
- Broad, Evidence-Backed Test Menu: One of the most comprehensive oncology testing portfolios available, spanning early to late-stage cancer care and supported by thousands of peer-reviewed publications.
- Seamless EHR Integration: Designed to fit within existing clinical workflows, reducing friction for providers and ensuring insights are available where decisions are made.
- Improved Diagnostic Accuracy: Validated methodologies such as tumor-normal matched sequencing reduce false positives by 28%, and dual DNA+RNA testing identifies 29% more actionable fusions versus DNA alone.
- Patient Financial Accessibility: Transparent financial assistance program ensures testing is accessible to all U.S. patients, regardless of payer status.
Cons
- US-Centric Accessibility: Financial assistance programs and full service coverage are primarily designed for U.S.-based patients; international patients are limited to a self-pay option.
- Oncology-Only Scope: The platform is purpose-built for cancer care, making it unsuitable for providers operating outside of oncology specialties.
- Enterprise Clinical Setting Required: Tempus is designed for institutional oncology practices and cancer centers; it is not a consumer-facing or general-purpose healthcare tool.
Frequently Asked Questions
What types of molecular tests does Tempus Oncology offer?
Tempus offers a comprehensive portfolio including hereditary cancer panels (CancerNext®, BRCAplus®), solid tumor DNA/RNA sequencing (xT CDx, xT, xR, xF, xE), liquid biopsy MRD monitoring (xM), algorithmic biomarker tests (HRD, PD-L1, HER2, MMR), and pharmacogenomics testing (RightMed®).
How does Tempus integrate with existing clinical workflows?
Tempus integrates with EHR systems to deliver patient insights, test ordering, and AI-driven treatment recommendations directly within a provider's existing clinical environment. Tempus Hub and Tempus ONE are the primary workflow tools.
What is Tempus ONE?
Tempus ONE is an AI-enabled clinical assistant that provides oncologists with real-time access to patient insights, genomic data, and current treatment options at the point of care.
Is financial assistance available for patients who cannot afford testing?
Yes. All U.S.-based patients are eligible to apply for Tempus's financial assistance program regardless of insurance status. International patients have access to a self-pay option.
How is Tempus's clinical evidence validated?
Tempus's insights are supported by over 2,000 publications in leading scientific journals including JAMA Network Open, Journal of Clinical Oncology, and Nature Biotechnology, with demonstrated improvements in detection accuracy and actionable findings.
